Kenvue Inc. News
Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, and other products under the Tylenol, Nicorette, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair care, and sun and other care products under the Neutrogena, Aveeno, and OGX brand names. The Essential Health segment offers oral and baby, women's health, and wound care products under the Listerine, Johnson's, Band-Aid, and Stayfree brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey. Kenvue Inc. operates as a subsidiary of Johnson & Johnson.
see moreKenvue Inc. Market News
4d
Loeb Dumps 64% of Kenvue; Dividend, Q2 Outlook Now
- Kenvue (KVUE) saw a major shareholder cut and mixed institutional flows this week, alongside a newly announced dividend and an upcoming May 7 earnings report. This article summarizes the concrete events—Daniel Loeb's 64% stake reduction, notable increases from VanEck and American Century, Comerica's trim, the $0.2075/share dividend (4.7% yield), and consensus EPS of $0.26—then explains near-term implications for investors.
11d
KVUE Rally Driven by Kimberly‑Clark Deal Odds
This week KVUE's performance remained tied to merger-arbitrage dynamics around the pending Kimberly‑Clark acquisition. With no new filings or regulatory developments reported, investors are watching deal execution risk, regulatory approvals, and upcoming earnings as the primary catalysts for the stock.
18d
Kenvue Deal Nears Close; Interim CFO Appointed Now
Kenvue shareholders approved Kimberly‑Clark’s ~$48.7B acquisition and the company named Heather Howlett as interim CFO ahead of an expected second‑half 2026 close. With Q2 earnings due in early‑mid May, investors should focus on regulatory clearance, earnings commentary on deal progress, and any financial guidance or reserve disclosures.
25d
Kenvue Deal Nears Close After Shareholder Vote Now
Kenvue shareholders overwhelmingly approved Kimberly‑Clark’s $48.7B acquisition, clearing a major hurdle toward a H2 2026 close. Q1 results showed modest sales growth and an EPS beat, but high payout ratios and ongoing liability suits keep risk elevated until the transaction is finalized.
07 Apr at 14:10
Kenvue CFO Departure Raises Merger Risk for KVUE!!
Kenvue's CFO announced a May 12, 2026 departure, creating near-term financial leadership uncertainty as the company moves toward a pending Kimberly‑Clark acquisition. With shares trading close to the deal-implied value, investors face limited upside and should watch interim finance leadership and regulatory milestones.
31 Mar at 14:10
KVUE Earnings Beat, CFO Exit Alters Outlook Update
Kenvue reported a modest Q4 beat and began cost actions, but a surprise CFO departure during active Kimberly‑Clark merger preparations introduces near‑term governance risk. Investors should weigh deal stability and execution against leadership transition.
24 Mar at 14:11
Kenvue Deal Hits NZ Antitrust Review; KC Earnings!
Kenvue (KVUE) faces a fresh regulatory checkpoint after New Zealand's Commerce Commission issued a Statement of Preliminary Issues on the Kimberly‑Clark acquisition; Kimberly‑Clark's recent strong full-year results help reinforce the deal's financing outlook. This article summarizes the key developments, regulatory timeline, investor implications, and near-term risks to KVUE shares.